高尔基磷蛋白 3 的高表达与前列腺癌的侵袭性和不良预后相关。
Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer.
机构信息
Department of Pathology, Nanfang Hospital, Southern Medical University, 510515 Tonghe, Guangzhou, People's Republic of China.
出版信息
Diagn Pathol. 2012 Sep 24;7:127. doi: 10.1186/1746-1596-7-127.
BACKGROUND
To investigate the expression of Golgi phosphoprotein-3 (GOLPH3) in prostate cancer and determine its prognostic value.
METHODS
Immunohistochemical staining for GOLPH3 was performed on tissue microarrays of 342 prostate patients. The correlation between GOLPH3 expression with its clinicopathologic factors was also analyzed in order to determine its prognostic significance.
RESULTS
GOLPH3 expression of normal prostate tissues, benign prostate hyperplasia, high-grade prostatic intraepithelial neoplasia, and hormone-dependent prostate cancer (HDPC) did not show any statistically significant difference. In contrast, statistically significant difference was reported in moderate/intense GOLPH3 expression in cases diagnosed with HDPC and castration resistant prostate cancer (CRPC) (P < 0.0005). Moderate /intense expression of GOLPH3 was associated with androgen independence (P = 0.012), higher Gleason score (P = 0.017), bone metastasis (P = 0.024), higher baseline prostate-specific antigen (PSA) (P = 0.038), and higher PSA nadir (P = 0.032). A significantly negative correlation was found between moderate/intense GOLPH3 expression and disease-free survival (DFS) (HR = 0.28, P = 0.012) and overall survival (OS) (HR = 0.42, P = 0.027). Univariated analysis indicated that moderate/intense GOLPH3 expression created a significantly prognostic impact in patients with CRPC. On the other hand, multivariate analysis indicated that GOLPH3 was a significantly independent prognostic factor of DFS (P = 0.027) in all prostate cancer patients.
CONCLUSIONS
In this study, it was discovered that the overexpression of GOLPH3 is associated with the transition of prostate cancer from hormone sensitive phase to hormone refractory phase. GOLPH3 might be an important prognostic factor of DFS and OS in patients with prostate cancer. In totality, GOLPH3 could be used as a novel candidate in devising a more effective therapeutic strategy to tackle CRPC.
VIRTUAL SLIDES
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1452541171722856.
背景
研究高尔基体磷蛋白 3（GOLPH3）在前列腺癌中的表达，确定其预后价值。
方法
对 342 例前列腺患者的组织微阵列进行 GOLPH3 免疫组织化学染色。分析 GOLPH3 表达与临床病理因素的相关性，以确定其预后意义。
结果
正常前列腺组织、良性前列腺增生、高级别前列腺上皮内瘤变和激素依赖性前列腺癌（HDPC）中 GOLPH3 的表达无统计学差异。相反，在诊断为 HDPC 和去势抵抗性前列腺癌（CRPC）的病例中，GOLPH3 的中度/强烈表达有统计学差异（P < 0.0005）。GOLPH3 的中度/强烈表达与雄激素非依赖性（P = 0.012）、更高的 Gleason 评分（P = 0.017）、骨转移（P = 0.024）、更高的基线前列腺特异性抗原（PSA）（P = 0.038）和更高的 PSA 最低值（P = 0.032）相关。中度/强烈的 GOLPH3 表达与无病生存（DFS）（HR = 0.28，P = 0.012）和总生存（OS）（HR = 0.42，P = 0.027）呈显著负相关。单因素分析表明，在 CRPC 患者中，中度/强烈的 GOLPH3 表达具有显著的预后影响。另一方面，多因素分析表明，GOLPH3 是所有前列腺癌患者 DFS 的独立预后因素（P = 0.027）。
结论
在这项研究中，发现 GOLPH3 的过度表达与前列腺癌从激素敏感阶段向激素抵抗阶段的转变有关。GOLPH3 可能是前列腺癌患者 DFS 和 OS 的一个重要预后因素。总的来说，GOLPH3 可以作为一种新的候选物，用于制定更有效的治疗策略来治疗 CRPC。
Zotero 插件